ISSN (Print) - 0012-9976 | ISSN (Online) - 2349-8846

A+| A| A-

KIRLOSKAR CUMMINS-Expanded Capacity

EPW Research Foundation CIPLA New Projects CIPLA, which is next only to Glaxo in the domestic pharmaceuticals market in terms of market share, saw a mere 1.5 per cent increase in net profit in 1995-96, despite a 21.4 per cent growth in net sales and a 16.2 per cent rise in value of production. Though operating profit increased by 25 per cent, sharp increases in interest charges (up 41.1 per cent), depreciation provision (up 12 per cent) and tax provision (up 47.8 per cent) restricted the rise in the bottorn line.

Dear Reader,

To continue reading, become a subscriber.

Explore our attractive subscription offers.

Click here

Back to Top